Dyshidrosiform Bullous Pemphigoid
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
3628-3641-Pruritus in Selected Dermatoses
Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2016; 20: 3628-3641 Pruritus in selected dermatoses K. OLEK-HRAB 1, M. HRAB 2, J. SZYFTER-HARRIS 1, Z. ADAMSKI 1 1Department of Dermatology, University of Medical Sciences, Poznan, Poland 2Department of Urology, University of Medical Sciences, Poznan, Poland Abstract. – Pruritus is a natural defence mech - logical self-defence mechanism similar to other anism of the body and creates the scratch reflex skin sensations, such as touch, pain, vibration, as a defensive reaction to potentially dangerous cold or heat, enabling the protection of the skin environmental factors. Together with pain, pruritus from external factors. Pruritus is a frequent is a type of superficial sensory experience. Pruri - symptom associated with dermatoses and various tus is a symptom often experienced both in 1 healthy subjects and in those who have symptoms systemic diseases . Acute pruritus often develops of a disease. In dermatology, pruritus is a frequent simultaneously with urticarial symptoms or as an symptom associated with a number of dermatoses acute undesirable reaction to drugs. The treat - and is sometimes an auxiliary factor in the diag - ment of this form of pruritus is much easier. nostic process. Apart from histamine, the most The chronic pruritus that often develops in pa - popular pruritus mediators include tryptase, en - tients with cholestasis, kidney diseases or skin dothelins, substance P, bradykinin, prostaglandins diseases (e.g. atopic dermatitis) is often more dif - and acetylcholine. The group of atopic diseases is 2,3 characterized by the presence of very persistent ficult to treat . Persistent rubbing, scratching or pruritus. -
Immune Globulin Therapy
Immune Globulin Therapy Policy Number: Original Effective Date: MM.04.015 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 02/01/2013 Section: Prescription Drugs Place(s) of Service: Outpatient I. Description Intravenous immune globulin (IVIG) is a sterile, highly purified preparation of unmodified immunoglobulins, which are isolated from large pools of human plasma. IVIG is an infusion used to treat patients with inherited or acquired immune deficiencies. It provides passive immunity against infection by increasing a person’s antibody titer and antigen-antibody reaction potential. IVIG supplies a broad spectrum of IgG antibodies against bacterial, viral, parasitic, and mycoplasmal antigens. Subcutaneous immune globulin (Sub-q IG) is FDA approved for the treatment of patients with primary immune deficiency. It is injected under the skin using an infusion pump, which means patients can self-administer the product in a home setting. II. Criteria/Guidelines A. IVIG therapy is covered (subject to Limitations/Exclusions and Administrative Guidelines) for the following indications: 1. Treatment of primary immunodeficiencies, including: a. Congenital agammaglobulinemia ( X-linked agammaglobulinemia) b. Hypogammaglobulinemia c. Common variable immunodeficiency d. X-linked immunodeficiency with hyperimmunoglobulin M e. Severe combined immunodeficiency f. Wiskott-Aldrich syndrome 2. Idiopathic thrombocytopenic purpura (ITP) Immune Globulin Therapy 2 3. Prevention of graft-versus-host disease in non-autologous bone marrow transplant patients age 20 or older in the first 100 days after transplantation 4. Kawasaki syndrome when used in conjunction with aspirin 5. Prevention of infection in: a. HIV-infected pediatric patients b. Bone marrow transplant patients age 20 or older in the first 100 days after transplantation c. -
Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002
Department of Health & Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002 CHANGE REQUEST 2149 HEADER SECTION NUMBERS PAGES TO INSERT PAGES TO DELETE Table of Contents 2 1 45-30 - 45-31 2 2 NEW/REVISED MATERIAL--EFFECTIVE DATE: October 1, 2002 IMPLEMENTATION DATE: October 1, 2002 Section 45-31, Intravenous Immune Globulin’s (IVIg) for the Treatment of Autoimmune Mucocutaneous Blistering Diseases, is added to provide limited coverage for the use of IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita. Use J1563 to bill for IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid, and (5) Epidermolysis Bullosa Acquisita. This revision to the Coverage Issues Manual is a national coverage decision (NCD). The NCDs are binding on all Medicare carriers, intermediaries, peer review organizations, health maintenance organizations, competitive medical plans, and health care prepayment plans. Under 42 CFR 422.256(b), an NCD that expands coverage is also binding on a Medicare+Choice Organization. In addition, an administrative law judge may not review an NCD. (See §1869(f)(1)(A)(i) of the Social Security Act.) These instructions should be implemented within your current operating budget. DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted. CMS-Pub. -
Red, Weeping and Oozing P.51 6
DERM CASE Test your knowledge with multiple-choice cases This month–9 cases: 1. Red, Weeping and Oozing p.51 6. A Chronic Condition p.56 2. A Rough Forehead p.52 7. “Why am I losing hair?” p.57 3. A Flat Papule p.53 8. Bothersome Bites p.58 4. Itchy Arms p.54 9. Ring-like Rashes p.59 5. A Patchy Neck p.55 on © buti t ri , h ist oad rig D wnl Case 1 y al n do p ci ca use o er sers nal C m d u rso m rise r pe o utho y fo C d. A cop or bite ngle Red, Weleepirnohig a sind Oozing a se p rint r S ed u nd p o oris w a t f uth , vie o Una lay AN12-year-old boy dpriesspents with a generalized, itchy rash over his body. The rash has been present for two years. Initially, the lesions were red, weeping and oozing. In the past year, the lesions became thickened, dry and scaly. What is your diagnosis? a. Psoriasis b. Pityriasis rosea c. Seborrheic dermatitis d. Atopic dermatitis (eczema) Answer Atopic dermatitis (eczema) (answer d) is a chroni - cally relapsing dermatosis characterized by pruritus, later by a widespread, symmetrical eruption in erythema, vesiculation, papulation, oozing, crust - which the long axes of the rash extend along skin ing, scaling and, in chronic cases, lichenification. tension lines and give rise to a “Christmas tree” Associated findings can include xerosis, hyperlin - appearance. Seborrheic dermatitis is characterized earity of the palms, double skin creases under the by a greasy, scaly, non-itchy, erythematous rash, lower eyelids (Dennie-Morgan folds), keratosis which might be patchy and focal and might spread pilaris and pityriasis alba. -
Photodermatoses Update Knowledge and Treatment of Photodermatoses Discuss Vitamin D Levels in Photodermatoses
Ashley Feneran, DO Jenifer Lloyd, DO University Hospitals Regional Hospitals AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY Objectives Review key points of several photodermatoses Update knowledge and treatment of photodermatoses Discuss vitamin D levels in photodermatoses Types of photodermatoses Immunologically mediated disorders Defective DNA repair disorders Photoaggravated dermatoses Chemical- and drug-induced photosensitivity Types of photodermatoses Immunologically mediated disorders Polymorphous light eruption Actinic prurigo Hydroa vacciniforme Chronic actinic dermatitis Solar urticaria Polymorphous light eruption (PMLE) Most common form of idiopathic photodermatitis Possibly due to delayed-type hypersensitivity reaction to an endogenous cutaneous photo- induced antigen Presents within minutes to hours of UV exposure and lasts several days Pathology Superficial and deep lymphocytic infiltrate Marked papillary dermal edema PMLE Treatment Topical or oral corticosteroids High SPF Restriction of UV exposure Hardening – natural, NBUVB, PUVA Antimalarial PMLE updates Study suggests topical vitamin D analogue used prophylactically may provide therapeutic benefit in PMLE Gruber-Wackernagel A, Bambach FJ, Legat A, et al. Br J Dermatol, 2011. PMLE updates Study seeks to further elucidate the pathogenesis of PMLE Found a decrease in Langerhans cells and an increase in mast cell density in lesional skin Wolf P, Gruber-Wackernagel A, Bambach I, et al. Exp Dermatol, 2014. Actinic prurigo Similar to PMLE Common in native -
Bullous Pemphigoid: Trigger and Predisposing Factors
biomolecules Review Bullous Pemphigoid: Trigger and Predisposing Factors , , Francesco Moro * y , Luca Fania * y, Jo Linda Maria Sinagra, Adele Salemme and Giovanni Di Zenzo First Dermatology Clinic, IDI-IRCCS, Via Dei Monti di Creta 104, 00167 Rome, Italy; [email protected] (J.L.M.S.); [email protected] (A.S.); [email protected] (G.D.Z.) * Correspondence: [email protected] (F.M.); [email protected] (L.F.); Tel.: +39-(342)-802-0004 (F.M.) These authors have equally contributed to the manuscript. y Received: 7 September 2020; Accepted: 8 October 2020; Published: 10 October 2020 Abstract: Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and BP230. Its pathogenesis depends on the interaction between predisposing factors, such as human leukocyte antigen (HLA) genes, comorbidities, aging, and trigger factors. Several trigger factors, such as drugs, thermal or electrical burns, surgical procedures, trauma, ultraviolet irradiation, radiotherapy, chemical preparations, transplants, and infections may induce or exacerbate BP disease. Identification of predisposing and trigger factors can increase the understanding of BP pathogenesis. Furthermore, an accurate anamnesis focused on the recognition of a possible trigger factor can improve prognosis by promptly removing it. Keywords: bullous pemphigoid; autoimmune bullous disease; trigger factors; predisposing factors; etiopathogenesis 1. Introduction Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, affecting predominantly elderly people. It is characterized by generalized pruritic urticarial plaques and tense subepithelial blisters. BP autoantibodies are directed mainly against two hemidesmosomal proteins, BP180 (also termed type XVII collagen) and BP230, which are components of the dermo-epidermal junction (DEJ) [1]. -
Bullous Pemphigoid/Pemphigus and Administration of the Pfizer/Biontech Vaccine (Comirnaty®). Introduction the Pfizer/Bionte
Bullous Pemphigoid/Pemphigus and administration of the Pfizer/BioNTech vaccine (Comirnaty®). Introduction The Pfizer/BioNTech vaccine (Comirnaty®) is a COVID-19-mRNA-vaccine (nucleoside modified). It is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. [1] The nucleoside-modified messenger RNA in Comirnaty® is formulated in lipid nanoparticles, which enable delivery of the nonreplicating RNA into host cells to direct transient expression of the SARS-CoV-2 S antigen. The mRNA codes for membrane-anchored, full-length Spike glycoprotein with two point mutations within the central helix. [1] Comirnaty® has been registered in Europe since December 21st, 2020. Bullous skin diseases are a group of dermatoses characterized by blisters and bullae in the skin and mucous membranes. The most common are pemphigus and bullous pemphigoid (BP). Pemphigus and bullous pemphigoid are autoantibody-mediated blistering skin diseases. In pemphigus, keratinocytes in epidermis and mucous membranes lose cell-cell adhesion, and in pemphigoid, the basal keratinocytes lose adhesion to the basement membrane. Bullous pemphigoid is a more common disease than pemphigus [2]. Bullous pemphigoid is the most common heterogeneous subepidermal autoimmune blistering disease (incidence 7 per million person year) [3,4], with an increasing prevalence after the age of 70, although it can also occur in the younger. It is characterized by auto-antibodies against different structural proteins of the hemidesmosomes in the epidermal basement membrane zone (EBMZ). Bullous pemphigoid typically causes severe pruritus with predominantly cutaneous lesions consisting of tense (fluid filled) bullae, erythema, and urticarial plaques. -
Dermatitis Herpetiformis
Dermatitis herpetiformis Authors: Professors Paolo Fabbri 1 and Marzia Caproni Creation date: November 2003 Update: February 2005 Scientific editor: Professor Benvenuto Giannotti 1II Clinica Dermatologica, Dipartimento di Scienze Dermatologiche, Università degli Studi di Firenze, Via degli Alfani 37, 50121, Firenze, Italy. [email protected] Summary Keywords Disease name and synonyms Definition Prevalence Clinical manifestations Differential diagnosis Etiopathogenesis Management – treatment Diagnostic criteria – methods References Summary Dermatitis herpetiformis (DH) is a subepidermal bullous disease characterized by chronic recurrence of itchy, erythematous papules, urticarial wheals and grouped vesicles that appear symmetrically on the extensor surfaces, buttocks and back. Children and young adults are mostly affected. Prevalence is estimated to be about 10 to 39 cases/100,000/year, with incidence ranging from 0,9 (Italy) to 2,6 (Northern Ireland) new cases/100,000/year. The disease is the cutaneous expression of a gluten-sensitive enteropathy identifiable with celiac disease. The clinical and histological pictures of both entities are quite similar. Granular IgA deposits at the dermo-epidermal junction, neutrophils and eosinophils together with activated CD4+ Th2 lymphocytes are supposed to represent the main immune mechanisms that co- operate in the pathogenesis of the disease. A strict gluten withdrawal from diet represents the basis for treatment. Keywords autoimmune bullous diseases, celiac disease, tissue transglutaminase, anti-endomysium antibodies, anti- tissue transglutaminase antibodies, gluten sensitivity, dapsone. deposits at the dermal papillae represent the immunological marker of the disease, that is strictly associated with a gluten-sensitive Disease name and synonyms enteropathy (GSE), indistinguishable from celiac - Dermatitis herpetiformis (DH), disease (CD). 1 - Duhring-Brocq disease, - Duhring’s dermatitis. -
Frontiers in Dermatology and Venereology - a Series of Theme Issues in Relation to the 100-Year Anniversary of Actadv
ISSN 0001-5555 ActaDV Volume 100 2020 Theme issue ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Frontiers in Dermatology and Venereology - A series of theme issues in relation to the 100-year anniversary of ActaDV Official Journal of - European Society for Dermatology and Psychiatry Affiliated with - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv ACTA DERMATO-VENEREOLOGICA The journal was founded in 1920 by Professor Johan Almkvist. Since 1969 ownership has been vested in the Society for Publication of Acta Dermato-Venereologica, a non-profit organization. Since 2006 the journal is published online, independently without a commercial publisher. (For further information please see the journal’s website https://www. medicaljournals.se/acta) ActaDV is a journal for clinical and experimental research in the field of dermatology and venereology and publishes high- quality papers in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as Correspondence to the Editor to stimulate debate. New books are also reviewed. The journal has rapid publication times. Editor-in-Chief: Olle Larkö, MD, PhD, Gothenburg Former Editors: Johan Almkvist 1920–1935 Deputy Editors: Sven Hellerström 1935–1969 -
Benign Chronic Bullous Dermatosis of Childhood." Are These Immunologic Diseases?
THE J OUItNAL OF INVEST IGATIVE DERMATOLOGY. 65:447-450, 1975 Vol. 65, No.5 Copyrig ht © 1975 by The Willia ms & Wilkins Co. Printed in U.S.A. JUVENILE DERMATITIS HERPETIFORMIS VERSUS "BENIGN CHRONIC BULLOUS DERMATOSIS OF CHILDHOOD." ARE THESE IMMUNOLOGIC DISEASES? TADEUSZ P. CHqRZELSK I, M.D., STAFANIA JABLONSKA, M .D ., ElmsT E. BEUTNER, PHD., EWA MACIEJOII'SI( A, M.D., AND MAlliA JAIlZAI3EI\ - CI-IOIlZELSKA , PHD. Department of Dermatology, Warsaw School of M edicine. Warsaw, Poland, and Department of Microbiology, State University of N ew York at Buffalo, Buffalo, N ew York , U. S. A. Seven cases of juvenile dermatitis herpetiformis have been investigated. Immunofluores cence a nd histologi c studies were made in all and jej unal biopsies in three. Immunopathologic results were positive in all cases including one that had previously been reported to be negative. Two groups could be distinguished according to clinical a nd histologic criteria, response to sulfapyridine, and character of the immunoglobulin depOSits. The first corresponded to dermatitis herpeti['ormis (DH) of adults, with characteristic lesions of the jejunal mucosa; the second corresponded either to bullous pemphigoid (BP), although in the majority of the cases without circulating anti basement-membrane antibodies, or to a mixed type with the combined features 0[' DH and BP. Repeated biopsies with seri al sections are essential for demonstrating immune depo its. The question arises whether any immunologically negative cases of " benign chronic bullous dermatosis of childhood" actuall y exist. In a previous paper (1] we have noted that informa tion was contributed by repeated immunologic . -
Dermatological Disorders in Tuvalu Between 2009 and 2012
MOLECULAR MEDICINE REPORTS 12: 3629-3631, 2015 Dermatological disorders in Tuvalu between 2009 and 2012 LI-JUNG LAN1,2, YING-SHUANG LIEN2,3, SHAO-CHUAN WANG2,4, NESE ITUASO-CONWAY5, MING-CHE TSAI2,6, PAO-YING TSENG6, YU-LIN YEH1, CHUN-TZU CHEN7, KO‑HUANG LUE2,8, JING-GUNG CHUNG9,10 and YU-PING HSIAO1,2 1Department of Dermatology, Chung Shan Medical University Hospital, Taichung 40201; 2Institute of Medicine, School of Medicine, Chung Shan Medical University, Taichung 40201; Departments of 3Obstetrics and Gynecology, and 4Urology, Chung Shan Medical University Hospital, Taichung 40201; 5Public Health, Princess Margaret Hospital, Ministry of Health, Funafuti, Tuvalu; 6International Medical Service Center, Chung Shan Medical University Hospital, Taichung 40201; Departments of 7Chief Secretary Group and 8Pediatrics, Chung Shan Medical University Hospital, Taichung 40201; 9Department of Biological Science and Technology, China Medical University, Taichung 40201; 10Department of Biotechnology, Asia University, Taichung 41354, Taiwan, R.O.C. Received July 1, 2014; Accepted September 18, 2014 DOI: 10.3892/mmr.2015.3806 Abstract. There is a distinct lack of knowledge on the land area of Tuvalu is only 25.9 km2, and the highest point does prevalence of skin disorders in Tuvalu. The aim of the current not exceed 4 m above sea level (1). Currently, an estimated study was to assess the prevalence of cutaneous diseases and 11,000 people live in Tuvalu (1). The Taiwan International to evaluate access dermatological care in Tuvalu. Cutaneous Cooperation and Development Fund (Taiwan ICDF) has disorders in the people of Tuvalu between 2009 and 2012 coordinated the medical resources of Taiwanese hospitals in were examined. -
Transcription
Amethyst: Welcome, everyone! This call is now being recorded. I would like to thank you for being on the call this evening and to our Sponsors Genentech, Principia Biopharma, Argenx, and Cabaletta Bio for making today’s call possible. Today’s topic is Peer Support to answer your question about living with pemphigus and pemphigoid with the IPPF’s Peer Health Coaches. So before we begin, I want to take a quick poll to see how many of you have connected with an IPPF Peer Health Coach (either by phone or email)? While you are answering the poll let me introduce you to the IPPF Peer Health coaches: Marc Yale is the Executive Director of the IPPF and also works as a PHC. Marc was diagnosed in 2007 with Cicatricial Pemphigoid, a rare autoimmune blistering skin disease. Like others with a rare disease, he experienced delays in diagnosis and difficulty finding a knowledgeable physician. Eventually, Marc lost his vision from the disease. This inspired him to help others with the disease. In 2008, he joined the IPPF as a Peer Health Coach. Becky Strong is the Outreach Director of the International Pemphigus & Pemphigoid Foundation and also works as a PHC. She was diagnosed with pemphigus vulgaris in 2010 after a 17-month journey that included seeing six different doctors from various specialties. She continues to use this experience to shine a light on the average pemphigus and pemphigoid patient experience of delayed diagnosis and bring attention to how healthcare professionals can change the patient experience. Mei Ling Moore was diagnosed with Pemphigus Vulgaris in February of 2002.